Topical Coenzyme Q10 versus Curcumin for oral leukoplakia treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will enroll patients with clinically and histologically confirmed homogeneous oral leukoplakia whose lesions are accessible for topical application. Participants will apply a topical CoQ10 gel or a topical curcumin gel according to the study protocol and return for scheduled follow-up visits. Investigators will record clinical outcomes such as lesion size and appearance and collect salivary samples to measure oxidative stress–related biomarkers. Key exclusions include moderate-to-severe dysplasia or cancer, other visible oral lesions, recent antioxidant use, active periodontal disease, pregnancy or significant systemic illness to avoid confounding results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinically and histologically diagnosed with homogeneous oral leukoplakia not indicated for surgical excision .
* Lesions accessible for topical application.
* Willing to sign informed consent and comply with study instructions and return to follow up

Exclusion Criteria:

* Moderate-to-severe dysplasia, carcinoma in situ, or invasive oral cancer.
* Presence of any visible oral lesions except for oral leukoplakia.
* Active periodontal diseases as this can confound salivary biomarkers.
* Significant systemic illness or immunosuppression.
* Patients who have taken systemic or topical antioxidant supplements within the last four weeks will be excluded to avoid confounding effects on salivary biomarkers.
* Pregnant and lactating women will be excluded due to hormonal changes that may alter oxidative stress and ethical considerations.
* Patients unwilling or unable to comply with study requirements.

Where it's running

• Outpatient Clinic of Oral medicine Department, Faculty of Dentistry, Alexandria University, Egypt
  Alexandria, Egypt Recruiting

Study contacts

• Study coordinator: Tasnim Saleem, BDS
• Email: tasneemsleem63@gmail.com
• Phone: 010 28946295

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Salivary IL-8 and Serum IL-6 as Biomarkers to Distinguish Oral Premalignant Disorders in Smokers and Never-Smokers

  This study tests whether salivary IL-8 and blood IL-6 can help tell apart adults with oral premalignant conditions from those with healthy mouths, and whether smoking influences these markers.

  Recruiting British University In Egypt · Cairo · NCT07915570

• Topical and oral metformin to prevent or shrink oral leukoplakia

  This study will test whether using metformin both as a mouth application and as oral tablets can shrink or prevent early oral leukoplakia in adults with mild-to-moderate dysplasia.

  Recruiting Phase 2 Cairo University · Cairo · NCT07387900

• Using Optical Coherence Tomography to Diagnose Oral Cancer

  This study is testing if a special imaging technique called Optical Coherence Tomography can help doctors find oral cancer earlier and more accurately in patients with potentially harmful mouth conditions.

  Recruiting University of Palermo · Palermo · NCT06321003

• Combination treatment of pioglitazone and metformin for high-risk oral lesions

  This study is testing if a combination of two medications, pioglitazone and metformin, can help reduce the size and severity of precancerous oral lesions in patients with oral leukoplakia.

  Recruiting at 2 sites Phase 2 University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT05727761

• Predicting cancer risk in oral leukoplakia using MAGE-A markers

  This study is trying to see if certain markers in people with oral leukoplakia can help predict their risk of developing oral cancer.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen · NCT03975322

• Imiquimod cream for oral dysplasia

  This trial will test whether applying 5% imiquimod cream inside the mouth can shrink precancerous oral dysplasia and reduce abnormal cells in adults who cannot or do not want surgery.

  Recruiting Phase 1/2 University of Southern California · Los Angeles, California · NCT07210775

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.